Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01609348 · ClinicalTrials.gov registry record · NA
Venlafaxine for Depression in Alzheimer's Disease (DIADs-3)
A NA study of Depression and Alzheimers Disease, sponsored by Johns Hopkins University.
- Completed
- Registry status
- NA
- Development phase
- 5
- Enrollment target
- 2
- Study locations
NCT01609348: Completed NA study of Depression and Alzheimers Disease, sponsored by Johns Hopkins University.
NCT01609348 is a NA study of Depression and Alzheimers Disease that has completed, run by Johns Hopkins University. The registered enrollment target is 5 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01609348, a NA study of Depression and Alzheimers Disease, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will test the use of venlafaxine to treat the depression in Alzheimer's Disease. Venlafaxine works by increasing natural substances in the brain (serotonin and norepinephrine) that help maintain mental balance. Alzheimer's disease (AD) is the commonest neurodegenerative disease of aging and the cause of major financial and emotional burden to patients, families and caregivers, and society. Depression is a very common symptom of AD, affecting as many as 50% of patients over their illness. Depression in AD (Alzheimer's disease) contributes greatly to patient disability and caregiver distress. Neither psychosocial interventions nor psychotropic medications have proven effective to date for the treatment of depression in AD.Venlafaxine is approved by the U.S. Food and Drug Administration (FDA) for the treatment of major depression but it is not known whether or not it can help depression in Alzheimer's Disease.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Venlafaxine
Study Locations (2)
Maryland
- Johns Hopkins at Bayview - Baltimore
Pennsylvania
- Reading Hospital - West Reading
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2012-04 |
| Est. Completion | 2017-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01609348
The ClinicalTrials.gov registry entry for NCT01609348 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (99% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01609348 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Maryland, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01609348 about?
NCT01609348 is a clinical study titled "Venlafaxine for Depression in Alzheimer's Disease (DIADs-3)". This study will test the use of venlafaxine to treat the depression in Alzheimer's Disease. Venlafaxine works by increasing natural substances in the brain (serotonin and norepinephrine) that help maintain mental balance. Alzheimer's disease (AD) is the commonest neurodegenerative disease of aging a...
What is the current status of trial NCT01609348?
This trial is currently completed. It is a NA study. The enrollment target is 5 participants. The study started on 2012-04. Estimated completion is 2017-01.
What conditions does trial NCT01609348 study?
This clinical trial studies the following conditions: Depression, Alzheimers Disease.
What interventions are being tested in trial NCT01609348?
The interventions under investigation include: Placebo (DRUG), Venlafaxine (DRUG).
Who is sponsoring clinical trial NCT01609348?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01609348 being conducted?
This trial has 2 study locations across Maryland, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Reaching Out to Distressed Medical Residents, Fellows and Faculty
RECRUITING · NA
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
Cold and Heat Investigation to Lower Levels of Depression
RECRUITING · NA
-
Dosing rTMS for Depression Post-SCI
RECRUITING · NA
-
Exploring Virtual Reality Adventure Training Exergaming
RECRUITING · NA
-
Brief Interventions for Coping with Distress
RECRUITING · NA
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.